Juan Diego Mejia-Otero1,2, Perrin White2, Ximena Lopez2. 1. Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. 2. Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Abstract
Purpose: To analyze the effectiveness of gonadotropin-releasing hormone agonists (GnRHa) in suppressing the hypothalamic-pituitary gonadal (HPG) axis in transgender adolescents. Methods: Retrospective review of electronic medical records of transgender youth and children with central precocious puberty (CPP) treated with GnRHa. Blood levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, and/or estradiol at baseline and during treatment were compared between groups. Results: Data from 30 transgender and 30 patients with CPP were analyzed. Transgender patients were older with a mean age of 13.0±2.1 years versus 7.7±2.3 years in the CPP group, p<0.001. There were more patients assigned male at birth (AMAB) in the transgender group (56.7%) than males in the CPP group (30%), p<0.001. The transgender group had more patients with advanced puberty with 56% of patients having a Tanner stage of IV-V, versus none in the CPP group, p<0.01. GnRHa treatment resulted in LH, FSH, and testosterone levels that were similar in males with CPP versus transgender patients AMAB; suppression of LH and FSH levels was similar in females with CPP versus transgender patients assigned female at birth, but estradiol levels were higher in the latter (1.8±1.8 pg/mL vs. 9.4±9.7 pg/mL, respectively, p<0.001). FSH levels were lower in the transgender group treated with histrelin (0.8±0.8 mIU/mL vs. 1.9±1.2 mIU/mL in the leuprolide group, p=0.004). Conclusions: GnRHa are effective in suppressing the HPG axis in transgender youth, similar to that observed in children with CPP. Copyright 2021, Mary Ann Liebert, Inc., publishers.
Purpose: To analyze the effectiveness of gonadotropin-releasing hormone agonists (GnRHa) in suppressing the hypothalamic-pituitary gonadal (HPG) axis in transgender adolescents. Methods: Retrospective review of electronic medical records of transgender youth and children with central precocious puberty (CPP) treated with GnRHa. Blood levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, and/or estradiol at baseline and during treatment were compared between groups. Results: Data from 30 transgender and 30 patients with CPP were analyzed. Transgender patients were older with a mean age of 13.0±2.1 years versus 7.7±2.3 years in the CPP group, p<0.001. There were more patients assigned male at birth (AMAB) in the transgender group (56.7%) than males in the CPP group (30%), p<0.001. The transgender group had more patients with advanced puberty with 56% of patients having a Tanner stage of IV-V, versus none in the CPP group, p<0.01. GnRHa treatment resulted in LH, FSH, and testosterone levels that were similar in males with CPP versus transgender patients AMAB; suppression of LH and FSH levels was similar in females with CPP versus transgender patients assigned female at birth, but estradiol levels were higher in the latter (1.8±1.8 pg/mL vs. 9.4±9.7 pg/mL, respectively, p<0.001). FSH levels were lower in the transgender group treated with histrelin (0.8±0.8 mIU/mL vs. 1.9±1.2 mIU/mL in the leuprolide group, p=0.004). Conclusions: GnRHa are effective in suppressing the HPG axis in transgender youth, similar to that observed in children with CPP. Copyright 2021, Mary Ann Liebert, Inc., publishers.
Authors: Annelou L C de Vries; Thomas D Steensma; Theo A H Doreleijers; Peggy T Cohen-Kettenis Journal: J Sex Med Date: 2010-07-14 Impact factor: 3.802
Authors: Annelou L C de Vries; Jenifer K McGuire; Thomas D Steensma; Eva C F Wagenaar; Theo A H Doreleijers; Peggy T Cohen-Kettenis Journal: Pediatrics Date: 2014-09-08 Impact factor: 7.124
Authors: Wylie C Hembree; Peggy T Cohen-Kettenis; Louis Gooren; Sabine E Hannema; Walter J Meyer; M Hassan Murad; Stephen M Rosenthal; Joshua D Safer; Vin Tangpricha; Guy G T'Sjoen Journal: J Clin Endocrinol Metab Date: 2017-11-01 Impact factor: 5.958
Authors: Rodrigo R Munhoz; Allan A L Pereira; André D Sasse; Paulo M Hoff; Tiffany A Traina; Clifford A Hudis; Ricardo J Marques Journal: JAMA Oncol Date: 2016-01 Impact factor: 31.777
Authors: Nicos Skordis; Gary Butler; Martine C de Vries; Katharina Main; Sabine E Hannema Journal: Horm Res Paediatr Date: 2019-01-29 Impact factor: 2.852
Authors: Kanthi Bangalore Krishna; John S Fuqua; Alan D Rogol; Karen O Klein; Jadranka Popovic; Christopher P Houk; Evangelia Charmandari; Peter A Lee; A V Freire; M G Ropelato; M Yazid Jalaludin; J Mbogo; C Kanaka-Gantenbein; X Luo; E A Eugster; K O Klein; M G Vogiatzi; K Reifschneider; V Bamba; C Garcia Rudaz; P Kaplowitz; P Backeljauw; D B Allen; M R Palmert; J Harrington; G Guerra-Junior; T Stanley; M Torres Tamayo; A L Miranda Lora; A Bajpai; L A Silverman; B S Miller; A Dayal; R Horikawa; S Oberfield; A D Rogol; T Tajima; J Popovic; S F Witchel; S M Rosenthal; C Finlayson; S E Hannema; M F Castilla-Peon; V Mericq; P G Medina Bravo Journal: Horm Res Paediatr Date: 2019-07-18 Impact factor: 2.852
Authors: Jean-Claude Carel; Erica A Eugster; Alan Rogol; Lucia Ghizzoni; Mark R Palmert; Franco Antoniazzi; Sheri Berenbaum; Jean-Pierre Bourguignon; George P Chrousos; Joël Coste; Sheri Deal; Liat de Vries; Carol Foster; Sabine Heger; Jack Holland; Kirsi Jahnukainen; Anders Juul; Paul Kaplowitz; Najiba Lahlou; Mary M Lee; Peter Lee; Deborah P Merke; E Kirk Neely; Wilma Oostdijk; Moshe Phillip; Robert L Rosenfield; Dorothy Shulman; Dennis Styne; Maïthé Tauber; Jan M Wit Journal: Pediatrics Date: 2009-03-30 Impact factor: 7.124